Bausch + Lomb to remain public amid deal negotiations of sale

Image credit: AdobeStock/AndreyPopov

Bausch + Lomb announces that it has no immediate plans to go private in an update provided by the company on a potential sale opportunity.¹ The update follows a request made by the Canadian Investment Regulatory Organization (CIRO) to explore the sale in December 2024.²

“Taking Bausch + Lomb private with a third-party buyer was one of several options being explored to complete a full separation from Bausch Health Companies Inc. After engagement with potential buyers, that process is complete, and will not result in a transaction at this time,” the company said in a statement. “Full separation remains the goal. Bausch + Lomb continues to operate as its own entity and execute on its strategies and business plan. The company, which raised 2024 revenue guidance on October 30, will report fourth-quarter and full-year 2024 earnings on February 19, in addition to providing guidance for the 2025 fiscal year.”

The sale of Bausch + Lomb would have completely separated the company from Bausch Health Companies Inc.¹

“While the company normally would not comment on deal negotiations, CIRO requested confirmation of a potential sale process given stock volatility often associated with market rumors,” Bausch + Lomb stated in a December 2024 news release. “Bausch + Lomb does not intend to provide additional detail until further disclosure is appropriate or necessary.”

Bausch + Lomb is currently traded on both the New York Stock Exchange and Toronto Stock Exchange.

References:

1. Bausch + Lomb provides update on potential sale. News release. Bausch + Lomb. February 6, 2025. Accessed February 10, 2025. https://www.bausch.com/news/?id=248

2. Bausch + Lomb responds to rumors of a potential sale. News release. Bausch + Lomb. December 12, 2024. Accessed February 10, 2025. https://www.bausch.com/news/?id=240